Latest News - Moderna
Top Corporates Hub
Moderna
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
08.09.2026 14:40
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Cancer Vaccines & Data Center Drama
08.09.2026 13:20
Data centers face drama as public pushback against the AI build-out is at a high.
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
08.09.2026 12:38
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
07.09.2026 11:02
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
05.09.2026 04:18
Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
05.09.2026 00:18
Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...
Why Moderna (MRNA) Stock Is Down Today
04.09.2026 01:35
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target to $81 from $40, representing a 46% downside from the previous day’s close of $150.81, CNBC reported.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
03.09.2026 17:24
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop
03.09.2026 15:16
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
03.09.2026 14:44
Bamco, the advisory arm of Ron Baron’s Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna shares nearly tripled on a positive Phase 3 report. Bamco also […]
Why Moderna's Cancer Vaccine Matters To Investors
03.09.2026 14:10
As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.
This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
03.09.2026 08:40
Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.
Rothschild & Co Downgrades Moderna to Sell, Raises Price Target to $81
03.09.2026 07:51
Rothschild & Co analyst Simon Baker downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $40 to $81.
Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery
02.09.2026 17:02
Alteogen's platform can turn intravenous biologics into injections, but payments depend on multiple products reaching milestones.
Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
02.09.2026 17:00
TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses Together, the long-term clinical and translational data further strengthen confidence in Transgene’s individualized neoantigen therapeutic vaccine approach and myvac® platform Strasbourg, France & Tokyo, Japan, September 2, 2026, 6:00 p.m. CET –
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says
02.09.2026 16:40
Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
02.09.2026 16:30
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?
02.09.2026 16:30
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
02.09.2026 16:30
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.